What is Epigenomics?
Epigenomics is a pioneering molecular diagnostics firm specializing in the development and commercialization of non-invasive, blood-based screening tests for cancer detection. By leveraging its proprietary DNA methylation biomarker technology, the company addresses significant medical needs in early-stage oncology. Its flagship product, Epi proColon, has achieved regulatory milestones, including FDA approval, and is currently deployed across international markets including the United States, Europe, and China. Beyond colorectal cancer screening, the company is actively expanding its clinical pipeline, with the Epi proLung test currently in development to address the high-mortality challenges associated with lung cancer detection.
How much funding has Epigenomics raised?
Epigenomics has raised a total of $168.5M across 12 funding rounds:
Stock Offering
$51.5M
Share Placement
$5.3M
Multiple Rounds
$15.2M
Debt
$7M
Share Placement
$6M
Share Placement
$24.3M
Share Placement
$8.2M
Share Placement
$4.4M
Stock Issuance/Offering (2004): $51.5M, investors not publicly disclosed
Share Placement (2014): $5.3M featuring BioChain Institute
Share Placement (2016): $7.4M backed by BioChain Institute
Share Placement (2016): $5.5M with participation from UChip Technology and BioChain
Share Placement (2016): $2.3M led by Cathay Fortune International Company Limited
Debt (2017): $7M, investors not publicly disclosed
Share Placement (2017): $6M, investors not publicly disclosed
Share Placement (2018): $24.3M, investors not publicly disclosed
Share Placement (2019): $8.2M, investors not publicly disclosed
Share Placement (2020): $4.4M, investors not publicly disclosed
Key Investors in Epigenomics
MPM Capital
MPM BioImpact manages early-stage venture funds, private/public impact funds and a public equities fund. We convert science into therapeutics to reach the patients that need them most.
Abingworth
Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams building world-class companies.
Wellcome Trust
Wellcome is an independent global charitable foundation based in London that supports discovery research and tackles urgent health challenges, funding science, policy and public engagement to improve health for people everywhere through grants, partnerships and advocacy.
What's next for Epigenomics?
With the recent strategic investment, Epigenomics is well-positioned to accelerate the commercial expansion of its existing diagnostic portfolio while simultaneously advancing its R&D pipeline. The company's focus remains on scaling the adoption of Epi proColon in key geographic territories and navigating the clinical validation pathways for its lung cancer diagnostic solutions. As the firm transitions into a more mature phase of enterprise-level operations, the focus will likely shift toward optimizing market penetration and strengthening its intellectual property moat in the competitive landscape of liquid biopsy and precision medicine.
See full Epigenomics company page
